NC525

A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

What's the purpose of the trial?

This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

Last Updated

1 month ago

Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There are 11 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

NC525 is a monoclonal antibody that targets LAIR-1 and is being studied for use in several different cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

NC525

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.